Despite the advancements in PD management, the available pharmacological treatments, such as levodopa, dopamine agonists, and monoamine oxidase-B (MAO-B) inhibitors, primarily provide symptomatic relief but do not halt the underlying neurodegenerative process [13,14]. Here, MAOB is linked to Parkinson disease.